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Abstract 
 
 There is well documented research surrounding the efficacy and utilization of metformin 
usage in patients with type II diabetes. It is a safe drug with minimal adverse side effects and has 
shown to have tremendous benefits for reducing A1C, aiding in weight loss, and improving 
sensitivity to insulin. This paper explores and reviews the research done surrounding possible 
implications of vitamin B12 deficiency, the challenges in distinguishing cause as its presentation 
can mimic peripheral neuropathy, and methods of screening and current guidelines. Future 
indications for research and important clinical pearls for clinicians providing care to these 
patients are included. The patient highlighted is of older age who is currently taking a 
combination oral hypoglycemic mediation that includes metformin. The importance of protecting 
and preventing permanent nerve damage is one of the main goals of monitoring for neuropathy, 
and vitamin B12 deficiency can mask this underlying process if diligence is not paid to proper 
and routine monitoring. The debate remains to how often, when, and what the best method for 
measuring vitamin B12 levels is.  
Keywords: Metformin, vitamin B12 deficiency, diabetes 
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Background 
 
Metformin has been around for a long time, with records demonstrating use at the time of 
Egyptian Pharaohs (Romero et al., 2017). It was approved by the Food and Drug Administration 
in 1995 for diabetes mellitus treatment in the United States; this was after Europe had been using 
it clinically and proved its safety and benefit for 20 years (Romero et al., 2017). However, while 
its introduction and use began as an antidiabetic agent, its treatment scope has expanded to 
prediabetes, gestational diabetes, and polycystic ovarian syndrome (Romero et al., 2017). 
Research has demonstrated clear health benefits for diabetic patients by mechanisms that 
decrease glucose absorption in the gastrointestinal tract, suppress glucose in both the liver and 
kidneys (Romero et al., 2017), increase glucose utilization in the peripheral tissues including the 
muscle and liver, lower lipids, aid in weight loss, and may even reduce all-cancer risk 
(McCulloch, 2018).  It also may demonstrate cardiovascular protective benefits and be safe for 
that patient population (Cheng, C.S. Leung, C.P. Leung, & Wong, 2018). 
With the overwhelming supporting evidence for the use of metformin and current 
recommendations of its utilization in diabetic patients, it’s important for providers to also 
consider some of the potential adverse effects of its long-term use that are repeatedly noted in 
research, perhaps in some cases even only demonstrated by anecdote or observation. One of 
these adverse effects includes vitamin B12 deficiency, which occurs in up to 30% of patients on 
long-term metformin therapy (McCulloch, 2018). Peripheral neuropathy may develop as a result 
of this, and furthermore may even precede the development of megaloblastic anemia 
(McCulloch, 2018).  
This report will investigate effects of vitamin B12 deficiency, the current guidelines 
surrounding vitamin B12 levels in patients taking metformin long-term, the benefits and 
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downfalls of doing so, and some recent evidence demonstrating a potential inaccuracy of serum 
vitamin B12 levels as a true indicator of deficiency. Clinically, what are the risks of not 
monitoring and checking vitamin B12 levels in this patient population? If the guidelines are not 
clear for clinical practice, how do providers navigate this to provide the best care for their 
patients? This literature review aims to address these questions.  
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Case Report 
 
A 65-year-old male presents to the clinic for a 6-month follow-up regarding his 
diabetes.  He currently has no complaints and states that he has been compliant in taking his 
medications.  He isn’t participating in regular exercise but works in his shop occasionally during 
the week.  His weight has gone up, but he blames it on “in the winter it’s too cold to do 
much.”  He is checking his blood sugars two to three times weekly, with varying results taken 
while fasting as well as pre and post prandial. He believes his morning fasting blood sugars 
range somewhere between 170-220.  
His current medication list includes Glipizide 10 mg daily, Lisinopril 10 mg daily, Toprol 
XL 50 mg daily, Zocor 20 mg daily, Janumet 50-1000 BID, Aspirin 81 mg daily, and a 
Multivitamin daily. He has no known allergies. Past medical history includes obesity, 
hyperlipidemia, DM Type II, and actinic keratosis. Past surgical history includes cataracts, colon 
polyp removal, and carpal tunnel. He doesn’t use tobacco products and drinks socially. He is due 
for pneumonia and tetanus vaccines as well as a colonoscopy screening.  
Upon reviewing systems, the patient denied any headaches or blurred vision. He denies 
any changes in urination patterns and reports normal stool patterns. He describes no 
hypoglycemic episodes. He reports having no chest pain or shortness of breath with exertion.  
Vital signs are as follows: blood pressure 138/80, pulse 72, respirations 18.  Current 
weight is 122 kg (269 lb) and BMI is 36.5. Labs are listed in the table below: 
 
Creatinine Urine 30.00 - 259.00 mg/dL 101.82 
Microalbumin mg/L mg/L 22.17 
Microalbumin/Creatinine Ratio 0 - 30 mg/g 22 
Hgb A1C  4%-5.6% 9.5 Abnormally high 
Cholesterol 0 - 200 mg/dL 133 
Triglyceride 30 - 150 mg/dL 167 Abnormally high  
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HDL 40 - 60 mg/dL 39 Abnormally low  
LDL 0 - 129 mg/dL 61 
Fasting Yes, No, Unknown Yes 
Glucose 70-100 mg/dL 324 Abnormally high 
BUN 7 - 18 mg/dL 16 
Creatinine 0.70 - 1.30 mg/dL 0.92 
BUN/Creatinine Ratio 15.0 - 20.0 17.4 
Sodium 136 - 145 meq/L 139 
Potassium 3.5 - 5.1 meq/L 4.3 
Chloride 98 - 107 meq/L 102 
CO2 21 - 32 meq/L 28 
Anion Gap with K 6 - 20 meq/L 13 
Calcium 8.5 - 10.1 mg/dL 9 
Protein Total 6.4 - 8.2 g/dL 7.8 
Albumin 3.5 - 5.0 g/dL 4.7 
Alkaline Phosphatase 46 - 116 U/L 84 
AST - SGOT 15 - 37 U/L 19 
ALT - SGPT 12 - 78 U/L 30 
Bilirubin Total 0.2 - 1.0 mg/dL 1.1 Abnormally high 
 
There are several lab values here of concern. One of the most obvious is the hemoglobin 
A1C, which has gone from 8.1 (6 months ago) to 9.6 today. The blood sugar control in 
inadequate, so stepping up therapy is essential at this point. It is important to also focus on 
weight management by means of healthy diet and consistent exercise. A diabetic educator 
referral would be indicated at this point. He will need help revamping his diet as well as learning 
how to inject insulin, which is a medication that would be started at this point.  
The other lab result of concern is the lipid panel. Although the LDL level is normal, the 
triglycerides are elevated. This patient is currently taking a low-intensity statin. According to the 
American Diabetes Association (2018), patients who are between the ages of 40 and 75 with 
diabetes who do not have a history of atherosclerotic disease should be taking a moderate 
intensity statin along with lifestyle interventions.  
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Physical exam revealed no significant concerning findings. Heart sounds were regular 
with no murmur auscultated. Lung sounds were clear, and effort was unlabored. The patient had 
normal microfilament sensation per foot exam and had adequate perfusion and sensation to lower 
extremities.  
Current UptoDate guidelines (2019) recommend follow up specific to this patient that 
includes a routine diabetic clinic visit in 3 months, as A1C measures are not where they need to 
be, and we are adjusting the medication regimen. We may also see this patient back in a few 
weeks, as the Lisinopril dosage would be increased to get better blood pressure control, further 
aiming to prevent complications such as diabetic retinopathy, neuropathy, and cardiovascular 
complications (McCullough, 2019). Other labs are up to date. Close monitoring is essential until 
overall management is achieved.  
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Literature Review  
Mechanisms and Monitoring 
The research behind long-term use of metformin and B12 deficiency has been well 
documented (Hansen et al., 2018; Langan & Goodbred, 2017; Pawlak, 2017; Out, Koov, Lehert, 
Schalkwijk, & Stehouwer, 2018; Rodríguez-Gutiérrez, 2017), though controversial at times 
(Rodríguez-Gutiérrez, 2017). However, the current recommended guidelines for providers does 
not provide clear-cut indications for monitoring and treatment for this population (Rodríguez-
Gutiérrez, 2017). There has also been some investigation that has shown serum vitamin B12 to 
be an insufficient test to reveal true vitamin B12 deficiency (Out et al., 2018). A look at current 
research concludes that providers need to have an awareness of this potential adverse effect and 
use their best clinical judgement to appropriately screen and treat these patients when deemed 
necessary. Complications that occur because of vitamin B12 deficiency can be very serious and 
lead to a poorer quality of life.  
Although the mechanisms are not well understood (Farland et al., 2015; Hansen et al., 
2018; Pawlak, 2017; Wong et al., 2018), patients with type 2 diabetes who take metformin are 
more prone to developing vitamin B12 deficiency (Ahmed, Muntingh & Rheeder, 2017; Hansen 
et al., 2018; Pawlak, 2017; Wong et al., 2018). This may be due to metformin’s interference of 
calcium metabolism in the intestine (Wong et al., 2018). This affects the vitamin B12 intrinsic 
factor complex as it is calcium dependent (Pawlak, 2017; Wong et al., 2018). Presse (2016) 
agreed that calcium supplementation could be an effective modifier in the relationship between 
gastric acid inhibitors and vitamin B12 deficiency, and that the deficiency is less likely among 
those, who while taking gastric acid inhibitors, also took calcium supplements. Consequently, 
these factors may result in the vitamin B12 deficiency as the vitamin is malabsorbed (Out et al., 
2018; Pawlak, 2017; Wong et al., 2018) Hansen et al., (2018) also added that the addition of 
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PPI’s may exacerbate the deficiency by inhibiting the release of peptin and lowering acidity in 
the stomach, which in turn decreases the ability of the body to absorb the protein bound vitamin 
B12. This may point to further evidence of malabsorption being the main player in the 
mechanism of action.  
In older populations, prevalence of vitamin B12 deficiency has shown to be as high as 
53.2% in those who are diabetic and taking metformin compared to those that do not (Wong et 
al., 2018). Older patients not taking metformin can have vitamin B12 deficiencies that exceed 
30% (Campbell, 2018). How do we determine age-related changes against medication and other 
factors that may contribute to this? What defines long term use? The liver stores of vitamin B12 
in humans are impressive and can sometimes delay clinical symptoms for up to 10 years after 
deficiency onset (Langan & Goodbred, 2017). The studies reviewed aren’t conclusive about what 
defines long-term use duration; some elude to long-term use as being several years while other 
studies reveal absorption issues as early as 4 months (Zdilla, 2015).  
Complications 
Peripheral neuropathy is one of the most common complications of type 2 diabetes 
mellitus (Ahmed et al., 2017), and may result in part because of a vitamin B12 deficiency 
(Ahmed et al., 2017). The neuropathy of diabetes may be hard to distinguish from the neuropathy 
that presents from a deficiency of vitamin B12 and is often wrongly or misdiagnosed as such 
(Ahmed et al., 2017; Farland et al., 2015; Out et al., 2018; Rodríguez-Gutiérrez, 2017; Wong et 
al., 2018). Permanent nerve damage cannot be reversed if this is not caught in a timely manner 
(Farland et al., 2015; Out et al., 2018; Wong et al., 2018). These symptoms range from 
parasthesias, loss of cutaneous sensation, muscle weakness, abnormal reflexes, urinary and 
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bowel incontinence and loss of vision, among others (Zdilla, 2015). These permanent changes 
can be seen and reflected on imaging scans (Zdilla, 2015).  
Studies surrounding vitamin B12 related neuropathy are also inconclusive and difficult to 
make a case for (Ahmed et al., 2017; Out et al., 2018), as metformin may have neuroprotective 
effects by its ability to lower blood glucose (Campbell, 2018; Out et al., 2018) and abolish pain 
induced by activation of sensory neurons (Ahmed et al., 2017). In many cases, neuropathy may 
be the only clinical manifestation of vitamin B12 deficiency, and hematologic presentation may 
be absent (Ahmed et al., 2017). Research is difficult to obtain to determine the true relationship 
between metformin use and worsening peripheral neuropathy because of the deceptive and 
indirect nature of how neuropathy presents clinically (Ahmed et al., 2017).  
Screening 
There are currently conflicting recommendations regarding routine screening of vitamin 
B12 deficiency when considering the discontinuation of metformin. According to the American 
Diabetes Association, periodic measurement of vitamin B12 levels should be considered in those 
who are taking metformin, with special attention in those who also have anemia or peripheral 
neuropathy (Standards of Medical Care in Diabetes, 2019). Some sources reported that screening 
vitamin B12 levels for average-risk adults is not currently recommended (Langan & Goodbred, 
2017; Rodríguez-Gutiérrez, 2017), while others recommended reassessing metformin use for 
high risk populations (Langan & Goodbred, 2017). These high-risk populations use include those 
using the drug for more than 4 months (Langan & Goodbred, 2017). Another source 
recommended annual vitamin B12 screening for anyone on metformin; this is based on the 
Glucophage package insert (Farland et al., 2015). Langan & Goodbred (2017) further 
recommended routine screening for patients with gastric or small intestine resections, 
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inflammatory bowel disease, use of PPI’s or H2 blockers for more than 12 months, those who 
consider themselves to be vegan, and the older adult population (those older than 75 years).  
It is evident that a specific time and frequency to screen for vitamin B12 deficiency in 
patients taking metformin has not been established. However, the consensus could be assumed 
that anytime a clinical manifestation is suspected, diagnostic testing should be considered; 
perhaps screening could even be warranted without clinical manifestations (Out et al., 2018). 
Sources indicate a vitamin B12 level of less than 150 pg per mL diagnostic for a deficient level 
(Langan & Goodbred, 2017; Out et al., 2018). Caution in false high levels is indicated in patients 
with alcoholism, liver disease or altered hepatic clearance (Langan & Goodbred, 2017).  
Whether or not serum vitamin B12 levels are a true indicator of levels in the body is a 
controversial subject (Out et al., 2018). Measurement of serum methylmalonic acid (MMA) 
should be a consideration and utilized to confirm a true vitamin B12 deficiency in those who 
may be high risk, asymptomatic, with low-normal results on a serum vitamin B12 test (Langan & 
Goodbred, 2017; Out et al., 2018). MMA is a much more direct measure of vitamin B12 and its 
physiological function (Farland et al., 2015; Langan & Goodbred, 2017; Pawlak, 2017; 
Rodríguez-Gutiérrez, 2017).   
Serum MMA levels will rise when vitamin B12 levels are low, which can give a more 
accurate picture for clinicians (Out et al., 2018). The continual use of metformin over time has a 
progressive effect and continues to increase MMA levels, which further reduces vitamin B12 
levels (Out et al., 2018). Vitamin B12 is a major player in the conversion of methylmalonic acid 
to succinyl coenzyme A, which is important in neurological function in the body (Ahmed et al., 
2017; Langan & Goodbred, 2017; Pawlak, 2017;). Pawlak (2017) also discussed 
holotranscobalamin II homocysteine (HoloTC) levels as being a better measure of vitamin B12 
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status; it is the carrier of vitamin B12 into cells and has a short-half life. This measure can reveal 
early deficiency of active vitamin B12 (Pawlak, 2017).  
Another potential issue in diagnostic measuring is that in cases of high glucose 
concentration (most diabetics), vitamin B12 may be caught in plasma which would show a false 
high level, while the patient might actually have a deficiency (Pawlak, 2017). Pawlak theorized 
that metformin only has an impact on the vitamin B12 levels that are circulating in the body, and 
that it doesn’t affect intracellular levels (2017). Obviously, more research is needed to establish 
solid and accurate methods of measurement if we are to best move forward with the best 
treatment plans for patients.   
Treatment 
Intramuscular injections of cyanocobalamin or oral vitamin B12 are the current 
recommended treatment for deficiency (Pawlak, 2017), with the British Society for Hematology 
recommending every other day injections for up to three weeks for those who are experiencing 
neurological deficits (Langan & Goodbred, 2017). Neurological symptom progression such as 
nerve damage can possibly be stopped by supplementation of vitamin B12 (Farland et al., 2015) 
To maintain adequate vitamin B12 levels in diabetic patients taking metformin, a dose of 
25ug/day or higher may be warranted, with those who use other medications that affect gastric 
acidity potentially needing up to 250 ug/day to maintain therapeutic levels (Pawlak, 2017). 
Langan & Goodbred (2017) claimed that serum methylmalonic acid levels do not improve with 
oral vitamin B12 supplementation, though this hasn’t been studied thoroughly. If indeed 
methylmalonic acid levels are a better indicator of vitamin B12 levels in the body, one must 
consider route of replacement.  
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Regardless of the uncertainties and differing conclusions about which route and dosage of 
vitamin B12 supplementation is superior, clinicians must be diligent about prescribing adequate 
replacement in those patients in which it is reasonable and appropriate. Prophylactic vitamin B12 
supplementation is not discussed in this literature review nor was it noted in any of the articles as 
a consideration, though future studies may or may not explore that as a possible treatment 
adjunct for those with type II diabetes.  
Learning Points 
 
The focus and evaluation gathered from this literature synthesis is that there remains to be 
inconclusive evidence on the best diagnostic screening and frequency of vitamin B12 deficiency 
in long-term users of metformin. It is currently unclear because the signs and symptoms of 
diabetic neuropathy and vitamin B12 deficiency can manifest the same. We also haven’t 
established a gold standard of laboratory testing that would give us our best indicator of vitamin 
B12 status within the body. Until further guidelines are established, clinicians need to be aware 
of the ability to screen and treat when it is clinically indicated. We want to prevent complications 
that are irreversible and provide our patients with the best quality of life possible. In summary:  
• Vitamin B12 deficiency is a serious clinical consideration for patients who have been 
taking metformin long-term 
• Diabetic neuropathy manifestations can be masked due to the overlapping similar 
symptoms of vitamin B12 deficiency 
• It is reasonable for clinicians to screen vitamin B12 levels on a routine basis and treat 
with supplemental vitamin B12 based on clinical judgement so to avoid complications of 
deficiency 
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• More research is needed to establish accurate vitamin B12 deficiency diagnostic and 
screening guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LONG-TERM USE OF METFORMIN AND B12   16 
 
References 
Ahmed, M. A., Muntingh, G. L., & Rheeder, P. (2017). Perspectives on peripheral neuropathy as 
a consequence of metformin-induced vitamin B12 deficiency in T2DM. International 
Journal of Endocrinology, 2017, 1-6. doi:10.1155/2017/2452853  
Campbell, J. M., Stephenson, M. D., Courten, B. D., Chapman, I., Bellman, S. M., & 
Aromataris, E. (2018). Metformin use associated with reduced risk of cementia in 
patients with diabetes: A systematic review and meta-analysis. Journal of Alzheimer’s 
Disease, 65(4), 1225-1236. doi:10.3233/jad-180263  
Farland, M. Z., Mcpheeters, C. M., Renwick, R. C., Barlow, P. B., Williams, J. D., Keeble, D. S., 
& Franks, A. S. (2015). Comparison of patients receiving long-term metformin therapy 
and vitamin B12 monitoring. Journal of Pharmacy Technology, 31(4), 184-189. 
doi:10.1177/8755122515576207  
Hansen, C. S., Jensen, J. S., Ridderstråle, M., Vistisen, D., Jørgensen, M. E., & Fleischer, J. 
(2017). Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy 
in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 31(1), 202-
208. doi:10.1016/j.jdiacomp.2016.08.025  
Langan, R. C., & Goodbred, A. J. (2017). Vitamin B12 deficiency: recognition and management. 
American Family Physician, 96(6), 384-389. Retrieved March 14, 2019. 
McCulloch (2018). Metformin in the treatment of adults with type 2 diabetes mellitus. In J. 
Mulder, (Ed) UptoDate (Version 24.0) [Mobile application software] Retrieved on March 
14th, 2019 from https://play.google.com/store/apps/details?id=com.uptodate.android 
LONG-TERM USE OF METFORMIN AND B12   17 
 
McCulloch (2019). Overview of medical care in adults with diabetes mellitus. In J. Mulder (Ed), 
UptoDate (Version 24.0) [Mobile application software] Retrieved on March 22nd, 2019 
from https://play.google.com/store/apps/details?id=com.uptodate.android 
Out, M., Kooy, A., Lehert, P., Schalkwijk, C. A., & Stehouwer, C. D. (2018). Long-term 
treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of 
a randomized controlled 4.3 year trial. Journal of Diabetes and Its Complications, 32(2), 
171-178. doi:10.1016/j.jdiacomp.2017.11.001  
Pawlak, R. (2017). Vitamin B12 for diabetes patients treated with metformin. Journal of Family 
Medicine and Disease Prevention, 3(2), 1-12. doi:10.23937/2469-5793/1510057  
Presse, N., Perreault, S., & Kergoat, M.-J (2016). Vitamin B12 deficiency induced by the use of 
gastric acid inhibitors: Calcium supplements as a potential effect modifier. Journal of 
Nutrition, Health & Aging, 20(5), 569-573. https://doi-
org.ezproxylr.med.und.edu/10.1007/s12603-015-0605-x 
Rodríguez-Gutiérrez, R., Montes-Villarreal, J., Rodríguez-Velver, K. V., González-Velázquez, 
C., Salcido-Montenegro, A., Elizondo-Plazas, A., & González-González, J. G. (2017). 
Metformin use and vitamin B12 deficiency: Untangling the association. The American 
Journal of the Medical Sciences, 354(2), 165-171. doi:10.1016/j.amjms.2017.04.010  
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., . . . 
Grossman, L. I. (2018). Metformin, the aspirin of the 21st century. Obstetrical & 
Gynecological Survey, 73(2), 81-82. doi:10.1097/01.ogx.0000530433.33367.e9  
Standards of Medical Care in Diabetes - 2019. (2019, January). Retrieved March 14, 2019, from 
http://www.diabetes.org/diabetescare  
LONG-TERM USE OF METFORMIN AND B12   18 
 
Wong, C. W., Leung, C. S., Leung, C. P., & Cheng, J. N. (2018). Association of metformin use 
with vitamin B12 deficiency in the institutionalized elderly. Archives of Gerontology and 
Geriatrics, 79, 57-62. doi:10.1016/j.archger.2018.07.019  
Zdilla, M. J. (2015). Metformin with either histamine H2-receptor antagonists or proton pump 
inhibitors: A polypharmacy recipe for neuropathy via vitamin B12 depletion. Clinical 
Diabetes, 33(2), 90-95. doi:10.2337/diaclin.33.2.90 
 
 
